CM/PHR/22/5686- NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer
A Contract Award Notice
by NHS ENGLAND
- Source
- Find a Tender
- Type
- Framework (Supply)
- Duration
- 4 year (est.)
- Value
- £608M
- Sector
- HEALTH
- Published
- 03 Apr 2024
- Delivery
- 01 Apr 2024 to 31 Mar 2028 (est.)
- Deadline
- n/a
Concepts
Location
Please refer to Document 3, Schedule 8 in the ITO Documents for the list of purchasing points
Geochart for 2 buyers and 6 suppliers
2 buyers
- NHS England Leeds
6 suppliers
- Quantum Pharmaceutical Burnopfield
- Lloydspharmacy Clinical Homecare Coventry
- Baxter Healthcare Norfolk
- Sciensus Pharma Services Staffordshire
- Qualasept Wilshire
- Ith Pharma London
Description
Proposed NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer (Lots 1, 2, 3, 4 and 5)Tender Reference: CM/PHR/22/5686/01 Period of framework agreement: 1 April 2024 to 31 March 2028 (covering regions East of England, London, North of England and South East).
Total Quantity or Scope
CM/PHR/22/5686- NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer (Lots 1, 2, 3, 4 and 5) 1 April 2024 to 31 March 2028 -East, SouthEast, London, NOFE
Award Detail
1 | Quantum Pharmaceutical (Burnopfield)
|
2 | Lloydspharmacy Clinical Homecare (Coventry)
|
3 | Baxter Healthcare (Norfolk)
|
4 | Sciensus Pharma Services (Staffordshire)
|
5 | Qualasept (Wilshire)
|
6 | Ith Pharma (London)
|
Award Criteria
PRICE | _ |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Award on basis of price.
Reference
- FTS 010730-2024